Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).

Participants needed: 88
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Neurona TherapeuticsUpdated: Jun 9, 2026Locations: 35
Eligibility criteria

Male or Female, age ≥18 to ≤75 [+6]

Epilepsy due to other medical conditions and/or progressive neurologic disease [+9]

Read more
Status: Recruiting

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Neurona TherapeuticsUpdated: Jan 7, 2026Locations: 17
Eligibility criteria

Male or female, age 18-75 years. [+10]

Epilepsy due to other and/or progressive neurologic disease. [+10]

Read more